JP2020517629A5 - - Google Patents

Download PDF

Info

Publication number
JP2020517629A5
JP2020517629A5 JP2019556813A JP2019556813A JP2020517629A5 JP 2020517629 A5 JP2020517629 A5 JP 2020517629A5 JP 2019556813 A JP2019556813 A JP 2019556813A JP 2019556813 A JP2019556813 A JP 2019556813A JP 2020517629 A5 JP2020517629 A5 JP 2020517629A5
Authority
JP
Japan
Prior art keywords
adc
cancer
cells
antibody
cell
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2019556813A
Other languages
English (en)
Japanese (ja)
Other versions
JP2020517629A (ja
JP7402691B2 (ja
Filing date
Publication date
Priority claimed from GBGB1706245.6A external-priority patent/GB201706245D0/en
Priority claimed from GBGB1706252.2A external-priority patent/GB201706252D0/en
Priority claimed from GBGB1706249.8A external-priority patent/GB201706249D0/en
Priority claimed from GBGB1706250.6A external-priority patent/GB201706250D0/en
Priority claimed from GBGB1706246.4A external-priority patent/GB201706246D0/en
Priority claimed from GBGB1706248.0A external-priority patent/GB201706248D0/en
Priority claimed from GBGB1706251.4A external-priority patent/GB201706251D0/en
Priority claimed from GBGB1706247.2A external-priority patent/GB201706247D0/en
Priority claimed from GBGB1805189.6A external-priority patent/GB201805189D0/en
Application filed filed Critical
Priority claimed from PCT/EP2018/060214 external-priority patent/WO2018193104A1/en
Publication of JP2020517629A publication Critical patent/JP2020517629A/ja
Publication of JP2020517629A5 publication Critical patent/JP2020517629A5/ja
Application granted granted Critical
Publication of JP7402691B2 publication Critical patent/JP7402691B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2019556813A 2017-04-20 2018-04-20 抗ｃｄ２５抗体薬物複合体による併用療法 Active JP7402691B2 (ja)

Applications Claiming Priority (19)

Application Number Priority Date Filing Date Title
GBGB1706248.0A GB201706248D0 (en) 2017-04-20 2017-04-20 Combination therapy
GBGB1706251.4A GB201706251D0 (en) 2017-04-20 2017-04-20 Combination therapy
GB1706250.6 2017-04-20
GBGB1706247.2A GB201706247D0 (en) 2017-04-20 2017-04-20 Combination therapy
GB1706245.6 2017-04-20
GB1706252.2 2017-04-20
GB1706251.4 2017-04-20
GBGB1706250.6A GB201706250D0 (en) 2017-04-20 2017-04-20 Combination therapy
GBGB1706252.2A GB201706252D0 (en) 2017-04-20 2017-04-20 Combination therapy
GB1706247.2 2017-04-20
GB1706246.4 2017-04-20
GBGB1706246.4A GB201706246D0 (en) 2017-04-20 2017-04-20 Combination therapy
GB1706248.0 2017-04-20
GBGB1706249.8A GB201706249D0 (en) 2017-04-20 2017-04-20 Combination therapy
GBGB1706245.6A GB201706245D0 (en) 2017-04-20 2017-04-20 Combination therapy
GB1706249.8 2017-04-20
GBGB1805189.6A GB201805189D0 (en) 2018-03-29 2018-03-29 Combination therapy
GB1805189.6 2018-03-29
PCT/EP2018/060214 WO2018193104A1 (en) 2017-04-20 2018-04-20 Combination therapy with an anti-cd25 antibody-drug conjugate

Publications (3)

Publication Number Publication Date
JP2020517629A JP2020517629A (ja) 2020-06-18
JP2020517629A5 true JP2020517629A5 (enExample) 2021-05-27
JP7402691B2 JP7402691B2 (ja) 2023-12-21

Family

ID=62044725

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2019556813A Active JP7402691B2 (ja) 2017-04-20 2018-04-20 抗ｃｄ２５抗体薬物複合体による併用療法

Country Status (10)

Country Link
US (1) US11596696B2 (enExample)
EP (1) EP3612236A1 (enExample)
JP (1) JP7402691B2 (enExample)
KR (1) KR20190137847A (enExample)
CN (1) CN110582303A (enExample)
AU (1) AU2018253950A1 (enExample)
BR (1) BR112019021680A2 (enExample)
CA (1) CA3057744A1 (enExample)
MX (1) MX2019012465A (enExample)
WO (1) WO2018193104A1 (enExample)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR101995620B1 (ko) * 2012-10-12 2019-07-03 에이디씨 테라퓨틱스 에스에이 피롤로벤조디아제핀-항체 컨주게이트
CA3098103A1 (en) * 2018-05-23 2019-11-28 Adc Therapeutics Sa Molecular adjuvant
GB201908128D0 (en) 2019-06-07 2019-07-24 Adc Therapeutics Sa Pyrrolobenzodiazepine-antibody conjugates
JP2022536140A (ja) * 2019-06-10 2022-08-12 アーデーセー セラピューティクス ソシエテ アノニム 併用療法
GB201917254D0 (en) * 2019-11-27 2020-01-08 Adc Therapeutics Sa Combination therapy
GB202011993D0 (en) 2020-07-31 2020-09-16 Adc Therapeutics Sa ANTI-IL 13Ra2 antibodies
WO2022248268A1 (en) * 2021-05-28 2022-12-01 Adc Therapeutics Sa Combination therapy
US12706617B2 (en) 2023-04-27 2026-08-11 Hewlett Packard Enterprise Development Lp Selective filtering to reduce interferences in Wi-Fi communications
US12609718B2 (en) 2023-06-14 2026-04-21 Hewlett Packard Enterprise Development Lp WiFi-7 optimized split band architecture and method of operation
US20250295801A1 (en) * 2024-03-21 2025-09-25 Seagen Inc. Cd25 antibodies, antibody drug conjugates, and uses thereof

Family Cites Families (55)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4816567A (en) 1983-04-08 1989-03-28 Genentech, Inc. Recombinant immunoglobin preparations
HUT60768A (en) 1990-03-16 1992-10-28 Sandoz Ag Process for producing cd25 fixing molecules
AU2003295471B2 (en) 2002-11-15 2011-08-25 Genmab A/S Human monoclonal antibodies against CD25
JP5238936B2 (ja) 2005-03-25 2013-07-17 ジーアイティーアール，インク． Ｇｉｔｒ結合分子およびその使用
KR101704734B1 (ko) 2005-07-01 2017-02-09 이. 알. 스퀴부 앤드 선즈, 엘.엘.씨. 예정 사멸 리간드 1 (피디-엘1)에 대한 인간 모노클로날 항체
NZ567140A (en) 2005-10-07 2011-09-30 Exelixis Inc Azetidines as MEK inhibitors for the treatment of proliferative diseases
PT2175884T (pt) 2007-07-12 2016-09-21 Gitr Inc Terapias de combinação empregando moléculas de ligação a gitr
EA201500417A1 (ru) 2008-08-25 2015-11-30 Эмплиммьюн, Инк. Композиции антагонистов pd-1 и способы применения
IN2015DN02826A (enExample) 2009-09-03 2015-09-11 Merck Sharp & Dohme
US8907053B2 (en) 2010-06-25 2014-12-09 Aurigene Discovery Technologies Limited Immunosuppression modulating compounds
CA2833636A1 (en) 2011-04-20 2012-10-26 Amplimmune, Inc. Antibodies and other molecules that bind b7-h1 and pd-1
BR112015007184A2 (pt) 2012-10-02 2017-08-08 Bristol Myers Squibb Co combinação de anticorpos anti-kir e anticorpos anti-pd-1 para tratar câncer
PT2906253T (pt) 2012-10-12 2018-11-05 Medimmune Ltd Conjugados de anticorpo anti-psma de pirrolobenzodiazepina
EP2906297B1 (en) 2012-10-12 2017-12-06 ADC Therapeutics SA Pyrrolobenzodiazepine-antibody conjugates
PT2906252T (pt) 2012-10-12 2017-09-19 Medimmune Ltd Conjugados de anticorpo anti-her2 de pirrolobenzodiazepina
WO2014057114A1 (en) 2012-10-12 2014-04-17 Adc Therapeutics Sàrl Pyrrolobenzodiazepine-anti-psma antibody conjugates
BR112015008238A2 (pt) 2012-10-12 2017-11-28 Adc Therapeutics Sarl conjugados de pirrolbenzodiazepina-anticorpo anti-cd22
DK2906298T3 (en) 2012-10-12 2018-12-17 Adc Therapeutics Sa Pyrrolobenzodiazepine-antibody conjugates
WO2014057118A1 (en) 2012-10-12 2014-04-17 Adc Therapeutics Sarl Pyrrolobenzodiazepine-anti-cd22 antibody conjugates
KR101995620B1 (ko) * 2012-10-12 2019-07-03 에이디씨 테라퓨틱스 에스에이 피롤로벤조디아제핀-항체 컨주게이트
FR3008408B1 (fr) * 2013-07-11 2018-03-09 Mc Saf Nouveaux conjugues anticorps-medicament et leur utilisation en therapie
SMT202300039T1 (it) 2013-09-13 2023-03-17 Beigene Switzerland Gmbh Anticorpi anti-pd1 e loro uso come terapia e per diagnostica
RS64268B1 (sr) 2013-09-20 2023-07-31 Bristol Myers Squibb Co Kombinacija anti-lag-3 antitela i anti-pd-1 antitela za lečenje tumora
US10010624B2 (en) 2013-10-11 2018-07-03 Medimmune Limited Pyrrolobenzodiazepine-antibody conjugates
WO2015052533A1 (en) 2013-10-11 2015-04-16 Spirogen Sàrl Pyrrolobenzodiazepine-antibody conjugates
WO2015052534A1 (en) 2013-10-11 2015-04-16 Spirogen Sàrl Pyrrolobenzodiazepine-antibody conjugates
WO2015052535A1 (en) 2013-10-11 2015-04-16 Spirogen Sàrl Pyrrolobenzodiazepine-antibody conjugates
MX2016007965A (es) 2013-12-17 2016-10-28 Genentech Inc Terapia de combinacion que comprende agonistas de union a ox40 y antagonistas de union al eje pd-1.
KR20160146747A (ko) 2014-03-31 2016-12-21 제넨테크, 인크. 항혈관신생제 및 ox40 결합 효능제를 포함하는 조합 요법
GB201406767D0 (en) 2014-04-15 2014-05-28 Cancer Rec Tech Ltd Humanized anti-Tn-MUC1 antibodies anf their conjugates
WO2015191615A2 (en) * 2014-06-09 2015-12-17 Biomed Valley Discoveries, Inc. Combination therapies using agents that target tumor-associated stroma or tumor cells and alkylating agents
TWI726608B (zh) 2014-07-03 2021-05-01 英屬開曼群島商百濟神州有限公司 抗pd-l1抗體及其作為治療及診斷之用途
CN106604933B (zh) 2014-07-11 2021-08-10 文塔纳医疗系统公司 抗pd-l1抗体及其诊断用途
BR112017000672A2 (pt) 2014-07-15 2017-11-14 Genentech Inc composições para tratamento de câncer utilizando antagonistas de ligação de eixo pd-1 e inibidores de mek
JP6451133B2 (ja) 2014-08-01 2019-01-16 株式会社リコー 異常検知装置、異常検知方法、異常検知システム、及びプログラム
TW201619200A (zh) 2014-10-10 2016-06-01 麥迪紐有限責任公司 人類化抗－ｏｘ４０抗體及其用途
CA2966507A1 (en) 2014-11-03 2016-05-12 Genentech, Inc. Methods and biomarkers for predicting efficacy and evaluation of an ox40 agonist treatment
CN106999583A (zh) 2014-11-17 2017-08-01 豪夫迈·罗氏有限公司 包含ox40结合激动剂和pd‑1轴结合拮抗剂的组合疗法
CN107148285B (zh) 2014-11-25 2022-01-04 Adc治疗股份有限公司 吡咯并苯并二氮杂䓬-抗体缀合物
WO2016127052A1 (en) 2015-02-05 2016-08-11 Bristol-Myers Squibb Company Cxcl11 and smica as predictive biomarkers for efficacy of anti-ctla4 immunotherapy
GB201506405D0 (en) 2015-04-15 2015-05-27 Berkel Patricius H C Van And Howard Philip W Site-specific antibody-drug conjugates
GB201506388D0 (en) 2015-04-15 2015-05-27 Berkel Patricius H C Van And Cancer Res Technology Ltd And Howard Philip W Site-specific antibody-drug conjugates
GB201506393D0 (en) 2015-04-15 2015-05-27 Berkel Patricius H C Van And Howard Philip W Site-specific antibody-drug conjugates
GB201506394D0 (en) 2015-04-15 2015-05-27 Berkel Patricius H C Van And Howard Philip W Site-specific antibody-drug conjugates
GB201506402D0 (en) 2015-04-15 2015-05-27 Berkel Patricius H C Van And Howard Philip W Site-specific antibody-drug conjugates
GB201506389D0 (en) 2015-04-15 2015-05-27 Berkel Patricius H C Van And Howard Philip W Site-specific antibody-drug conjugates
GB201506407D0 (en) 2015-04-15 2015-05-27 Berkel Patricius H C Van And Howard Philip W Site-specific antibody-drug conjugates
GB201506409D0 (en) 2015-04-15 2015-05-27 Williams David G And Berkel Patricius H C Van And Howard Philip W Humanized anti-axl antibodies and their conjugates
GB201506399D0 (en) 2015-04-15 2015-05-27 Berkel Patricius H C Van And Howard Philip W Site-specific antibody-drug conjugates
HRP20201334T1 (hr) 2015-04-17 2020-11-27 Bristol-Myers Squibb Company Kompozicije koje sadrže kombinaciju ipilimumaba i nivolumaba
GB201507827D0 (en) 2015-05-07 2015-06-17 Adc Therapeutics Sarl Diagnostic test
EP3292152A1 (en) 2015-05-07 2018-03-14 Agenus Inc. Anti-ox40 antibodies and methods of use thereof
EP3304079B1 (en) 2015-06-03 2020-06-03 Bristol-Myers Squibb Company Anti-gitr antibodies for cancer diagnostics
MX2017016502A (es) 2015-06-29 2018-03-12 Univ Rockefeller Anticuerpos contra cd40 con actividad agonista mejorada.
GB201513607D0 (en) 2015-07-31 2015-09-16 Feingold Jay M Pyrrolobenzodiazepine-antibody conjugates

Similar Documents

Publication Publication Date Title
US20230149556A1 (en) Combination therapy
JP2020517640A5 (enExample)
JP7402691B2 (ja) 抗ｃｄ２５抗体薬物複合体による併用療法
JP6591428B2 (ja) 癌治療のためのｐｄ−１拮抗薬およびｖｅｇｆｒ阻害剤の組み合わせ
US20160355597A1 (en) Methods of treating cancer using anti-ox40 antibodies
WO2016200835A1 (en) Methods of treating cancer using anti-ox40 antibodies and pd-1 axis binding antagonists
JP2020517652A5 (enExample)
US20200129638A1 (en) Combination therapy with an anti-psma antibody-drug conjugate
JP7740994B2 (ja) 抗ｃｄ１９抗体薬物複合体とｐｉ３ｋ阻害剤又は二次薬剤を含む併用治療
JP2022536140A (ja) 併用療法
JP7590083B2 (ja) 併用療法
JP2021533090A (ja) 併用療法
KR20200106921A (ko) 암을 치료하기 위한 방법 및 조합 요법
WO2022248268A1 (en) Combination therapy
EA046551B1 (ru) Комбинированная терапия